Investigations of p-tolyloxy-1,3,4-oxadiazole propionamides as soybean 15-lipoxygenase inhibitors in comforting with in vitro and in silico studies

Inflammatory disorders are the prime contributor to public health issue and the development of more effective and safer anti-inflammatory drugs in addition to other therapeutic alternatives to treat inflammatory illnesses, particularly chronic inflammatory diseases, is one of the foremost current issues. In this regard, our present work is concerned with the synthesis of a new series of N-alkyl/aralkyl/aryl derivatives (7a-o) of 5-((p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-ylthio)propionamide which was instigated by the successive conversions of p-tolyloxyacetic acid into ester, hydrazide and 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol. The planned compounds (7a-o) were attained by the reaction of 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol with variety of N-alkyl/aralkyl/aryl electrophiles in potassium hydroxide and were characterized by FTIR, H-1-, C-13-NMR spectroscopy, EI-MS and HR-EI-MS spectrometry and probed for their inhibiting potential against soybean 15-lipoxygenase (15-LOX) enzyme. The compounds 7a, 7n, 7 g, 7e, 7h, 7i, 7j and 7b promulgated the potent inhibiting potential with IC50 values 9.43 +/- 0.45, 16.75 +/- 0.49, 19.45 +/- 0.37, 21.32 +/- 0.46, 22.64 +/- 0.56, 23.53 +/- 0.62, 24.32 +/- 0.45 and 29.15 +/- 0.57 mu M, respectively, while excellent to good inhibitory activities were shown by 7o, 7 m, 7k, 7f, 7c, 7 l and 7d with IC50 values in the range 30.29 +/- 0.56 to 52.54 +/- 0.64 mu M. Compounds 7i-o maintained 91.12 +/- 1.5 to 98.23 +/- 1.2% blood mononuclear cells (MNCs) viability at 0.25 mM by MTT assay whilst compounds 7d-h observed 46.51 +/- 1.3 to 57.12 +/- 1.4% viability where as the most toxic compounds were 7b (12.51 +/- 1.4%), 7a (28.12 +/- 1.5%) and 7c (38.23 +/- 1.5%) as compared with controls. Pharmacokinetic profiles predicted good oral bioavailability and drug-likeness properties of molecules as per rule of five. Molecular docking studies displayed hydrogen bonding between the compounds and the enzyme with Arg378 which was common in 7n, 7 g, 7h and baicalein. In 7a and quercetin, hydrogen bonding was established through Asn375; Tyr512 and Val589 were also involved in bonding with other analogues. RMSD (root mean square deviation) values exhibited good inhibitory profiles in the order quercetin (0.73 angstrom)<7 g (0.98 angstrom)

Automated summary

This study focuses on the synthesis of a new series of N-alkyl/aralkyl/aryl derivatives and their inhibiting potential against soybean 15-lipoxygenase enzyme. The compounds 7a, 7n, 7g, 7e, 7h, 7i, 7j, and 7b showed potent inhibitory activities, while compounds 7o, 7m, 7k, 7f, 7c, 7l, and 7d exhibited good inhibitory activities. Pharmacokinetic profiles indicated good oral bioavailability and drug-likeness properties of the compounds.